Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review

Critical Reviews in Oncology/Hematology - Netherlands
doi 10.1016/j.critrevonc.2016.11.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Vestnik dermatologii i venerologii
2019English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report

Drugs in R and D
Pharmacology
2014English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era

Bone Marrow Transplantation
TransplantationHematology
2017English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy